Financials
Financial year 2024
Worth noting
- The team shrank two years in a row.
- Little cash and receivables against the short-term debts.
Gross margin
€ 5.2 million
▼ 1% vs 2023
Profit
Growing€ 12.3 million
▲ 453% vs 2023
Debts
Low€ 21.9 million
▲ 1% vs 2023
A.forall Development from Anderlecht, company number BE0827869165, closed financial year 2024 with a result of € 12.3 million after tax. For that financial year A.forall Development recorded a gross margin of € 5.2 million and equity of € 39.3 million. Compared with financial year 2023, the result moved from € 2.2 million to € 12.3 million. Profitable, and profit is growing. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on September 9, 2025.
What happened at A.forall Development?
What happened at A.forall Development in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Steen Vangsgaard stepped down as director. NBB
- New annual accounts for financial year 2024: profit of € 12.3 million (▲ 453% vs 2023). filed late Source: NBB ↗
- Cellular Consulting stepped down as director. NBB
- LMDC GmbH stepped down as director. NBB
- Themtis BV stepped down as director. NBB
- Steen Vangsgaard became a director. NBB
- HFS BV stepped down as director. NBB
- LMDC GmbH became a director. NBB
In short
From € 28.3 million profit in 2021 to € 12.3 million profit in 2024.
Paid € 420,703 in corporate taxes since 2021.
Best year ever: 2021, with € 28.3 million profit.
On average € 495,200 of value added per employee in 2024.
A new publication or filing at A.forall Development? We notify you, reason included.
Follow A.forall DevelopmentNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
It owns 100% of NEOGEN, 100% of Generic Pharma International LTD., 100% of Generic Specialty Pharma LTD., 100% of A.forall Access Ltd. and 100% of Milla Pharmaceuticals Inc. itself.
Directors
According to the 2024 annual accounts
Director · represented by Filip Van de Vliet
Also active at: ECOPHARMASUPPLY DISTRIBUTION, ECO.PHARMA.SUPPLY, FYTEKO +2 more
since 2020 · until 2025
since 2025 · until 2031
Director · represented by Ivo Peeters
Also active at: NEOGEN, ECOPHARMASUPPLY DISTRIBUTION, IMPEXECO +3 more
since 2020 · until 2024
Director · represented by Bruno Cardoso Simoes Febra
since 2022 · until 2025
since 2024 · until 2025
Establishments
Establishment units
Physical locations of this company
Marie Curiesquare 50
1070 Anderlecht
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 5 companies are registered at this address.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
INFOMANIAK-AS, CH
Domain
Domain
aforallpharma.com
Registered
2023-07-24
Registrar
Infomaniak Network SA
Expires
2026-07-24
Website info
Features
Security
Network
Details
- Company number
- 0827.869.165
- VAT number
- BE 0827.869.165
- Registered office
- Marie Curiesquare 50, 1070 Anderlecht
- Names & denominations
- A.forall Development
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 15 July 2010
- Peppol
- Active · Active since 6 Jan 2026
- Contact
- aforallpharma.com
- Activities · NACE
Vervaardiging van geneesmiddelen
Activiteiten van holdings
Holdings